Edwards Lifesciences Corp

Edwards Lifesciences insider Lippis Daniel J. buys 12,820 shares in a quiet market, signaling confidence in the TAVR business and recent regulatory win. This move suggests long‑term upside despite short‑term volatility.

CEO Bernard J’s large buy of 25,350 Edwards Lifesciences shares shows bullish insider confidence, potentially boosting the stock past its 52‑week low.

Insider buying by Edwards Lifesciences’ chief valuation pro signals confidence amid a near 52‑week high and potential JenaValve deal, boosting investor optimism.